Components of the blood that cannot be assigned to one of the other above-mentioned groups of medicines.
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
Adzynma |
Takeda Manufacturing Austria AG |
EU/1/24/1837 | 01.08.2024 | |
FEIBA 500 E. konzentriert |
Takeda GmbH |
PEI.H.12158.04.1 | 20.01.2024 | |
FEIBA 1000 E. konzentriert |
Takeda GmbH |
PEI.H.12158.05.1 | 20.01.2024 | |
FEIBA 2500 E. konzentriert |
Takeda GmbH |
PEI.H.12158.06.1 | 20.01.2024 | |
|
Normosang |
Recordati Rare Diseases |
PEI.H.03381.01.1 | 15.10.2006 | |
|
Ondexxya |
Astrazeneca AB |
EU/1/18/1345 | 26.04.2019 | |
Prolastin 1000 mg |
Grifols Deutschland GmbH |
12944.01.00 | 14.12.1988 | |
Prolastin 4000 mg |
Grifols Deutschland GmbH |
12944.02.00 | 04.10.2023 | |
Prolastin 5000 mg |
Grifols Deutschland GmbH |
12944.03.00 | 04.10.2023 | |
|
Respreeza |
CSL Behring GmbH |
EU/1/15/1006 | 20.08.2015 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 17.06.2025
